X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P001-IO and Inlyta®(axitinib) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 16, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-IO, the company’s CXCR4 antagonist, has been selected for poster presentation at the 2018 Association Society of Clinical Oncology (ASCO) annual meeting, taking place June 1-5 in Chicago. The presentation will describe clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

This entry was posted in Recent Development News: Q2 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »